Dose Escalation Study Assessing the Safety and Immune Response of PPV-06 Vaccine

  • days left to enroll
  • participants needed
  • sponsor
    Peptinov SAS
Updated on 9 May 2022
body mass index


PPV-06 immunotherapy targets interleukin-6 (IL-6), a key molecule of the immune system whose overproduction is implicated in many inflammatory and autoimmune diseases such as rheumatoid arthritis and osteoarthritis. The benefit of vaccination with PPV-06 is to induce, in response to immunizations, the production of antibodies directed against IL-6. The antibodies produced will neutralize the biological activity of IL-6 involved in the body's inflammatory process.

The primary objective is to evaluate the safety/tolerability of vaccination with PPV-06.

Condition Knee Osteoarthritis
Treatment Placebo, PPV-06 10 μg, PPV-06 50 μg
Clinical Study IdentifierNCT04447898
SponsorPeptinov SAS
Last Modified on9 May 2022


Yes No Not Sure

Inclusion Criteria

Male or female aged over 40 years
Diagnosis of primary inflammatory Knee Osteoarthritis (KOA)
Body mass index (BMI) of 18-32 kg/m2 at screening
Patients with normal organ function at baseline
Contraceptives measures
In the investigator's opinion, the patient is capable and willing to comply with the requirements of the study
Willing and able to sign a written informed consent
Affiliated to social security insurance

Exclusion Criteria

Systemic Autoimmune or immunodeficiency disease
Administration of non-steroidal anti-inflammatory drug (NSAID)
Administration of prednisone or having intra-articular corticosteroid injection or bolus intramuscular or intravenous treatment with corticosteroids
Patients treated with biologics such as anti-TNFAlpha, anti-IL-6 and anti-CD-20
Participation in another investigational drug or vaccine trial
Knee surgery planned before screening and throughout the study
Knee surgery within the year of baseline
Knee trauma within 2 months of baseline
Chronic hepatitis B and/or C infection. Patients with previous infection, resolved in the past, are eligible
History of allergic reaction to any constituents of the study drug
Diagnosis or history of any inflammatory arthritis
Neurologic disorders involving the lower limbs
History of malignancy within the last 5 years
Uncontrolled congestive heart failure or hypertension, unstable heart disease
Evidence of any clinically significant abnormality on a chest X-ray which, in the opinion of the investigator, could represent active infection or latent tuberculosis
Moderate or severe acute illness/infection, persistent diarrhea or vomiting on the day of vaccination
Received any licensed, non-live vaccine within the 14 days before receipt of any dose of the study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of any dose of the study vaccine
Receipt of immune globulins, blood or blood-derived products
Pregnant or lactating females
The investigator considers the patient unfit for the study as a result of the medical interview, physical examination, or screening investigations
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note